Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered Via Magnetic Resonance Imaging (MRI)-Guided Convection-enhanced Delivery (CED)

NCT06063850 is registered in ClinicalTrials.gov with UniQure Biopharma B.V. as lead sponsor.

NCT NCT06063850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06063850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered Via Magnetic Resonance Imaging (MRI)-Guided Convection-enhanced Delivery (CED)
Lead sponsor
UniQure Biopharma B.V.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 12, 2024
Completion date
December 31, 2031
Enrollment
12 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

mesial temporal lobe epilepsy